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ABSTRACT
ObjeCtives
To study the association between maternal use of 
antidepressants during pregnancy and autism 
spectrum disorder (ASD) in offspring.
Design
Observational prospective cohort study with 
regression methods, propensity score matching, 
sibling controls, and negative control comparison.
setting
Stockholm County, Sweden.
PartiCiPants
254 610 individuals aged 4-17, including 5378 with 
autism, living in Stockholm County in 2001-11 who were 
born to mothers who did not take antidepressants and 
did not have any psychiatric disorder, mothers who 
took antidepressants during pregnancy, or mothers 
with psychiatric disorders who did not take 
antidepressants during pregnancy. Maternal 
antidepressant use was recorded during first antenatal 
interview or determined from prescription records.
Main OutCOMe Measure
Offspring diagnosis of autism spectrum disorder, with 
and without intellectual disability.
results
Of the 3342 children exposed to antidepressants 
during pregnancy, 4.1% (n=136) had a diagnosis of 
autism compared with a 2.9% prevalence (n=353) in 
12 325 children not exposed to antidepressants whose 
mothers had a history of a psychiatric disorder 
(adjusted odds ratio 1.45, 95% confidence interval 1.13 
to 1.85). Propensity score analysis led to similar 
results. The results of a sibling control analysis were in 
the same direction, although with wider confidence 
intervals. In a negative control comparison, there was 
no evidence of any increased risk of autism in children 
whose fathers were prescribed antidepressants during 
the mothers’ pregnancy (1.13, 0.68 to 1.88). In all 
analyses, the risk increase concerned only autism 
without intellectual disability.
COnClusiOns
The association between antidepressant use during 
pregnancy and autism, particularly autism without 
intellectual disability, might not solely be a byproduct 
of confounding. Study of the potential underlying 
biological mechanisms could help the understanding 
of modifiable mechanisms in the aetiology of autism. 
Importantly, the absolute risk of autism was small, 
and, hypothetically, if no pregnant women took 
antidepressants, the number of cases that could 
potentially be prevented would be small.
Introduction
Depression is common in women of childbearing age, 
and in Europe 3-8% of pregnant women are prescribed 
antidepressants during pregnancy.1  The fetal safety of 
antidepressant exposure during pregnancy has gener-
ated much debate after recent concerns of a possible 
association with autism in exposed offspring. In the 
past five years, several epidemiological studies2-11  have 
assessed the relation between antidepressant use 
during pregnancy and autism in offspring, but robust 
conclusions have been elusive.12 13 Although most stud-
ies found evidence of unadjusted associations, conclu-
sions differed because of concerns about “confounding 
by indication.” This was because depression or other 
psychiatric indications for antidepressant use could be 
associated with autism through genetic or non-genetic 
pathways, and thus the possibility of the observed 
associations representing the risk of autism from the 
underlying indication for prescription could not be 
ruled out.
All antidepressants cross the placental barrier and 
are available to the developing fetus.14  Most of the com-
monly used antidepressants such as selective serotonin 
reuptake inhibitors (SSRIs) increase the availability of 
serotonin in the synaptic cleft. The serotonergic system 
emerges early in embryogenesis and is critical for neu-
rodevelopment.15  In utero exposure to serotonergic 
antidepressants in animal models have reported asso-
ciations with autism-like behaviours in the offspring.16 
It is therefore biologically plausible that similar effects 
could be seen in humans. Disentangling a potential 
causal association of antidepressants on the risk of 
autism from that observed from confounding by indica-
tion is crucial to reduce clinical uncertainty and help 
women make informed decisions regarding the risks 
and benefits of antidepressant use during pregnancy.
WhAT IS AlReAdy knoWn ABouT ThIS TopIC
Several observational studies have reported associations between antidepressant 
use during pregnancy and autism in offspring
Whether this association is causal or confounded by indication is not clear
WhAT ThIS STudy AddS
This large cohort study used various methods to deal with confounding, including 
traditional multivariable regression, propensity score matching, sibling controls, 
and a negative control design
The results of all these analyses, which used different assumptions, seemed to be 
consistent with each other, suggesting that the association between in utero 
exposure to antidepressants and autism might not be fully explained by 
confounding
The absolute risks were small so results should not be considered alarming, but the 
findings could be useful in a further understanding of the aetiology of autism
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In the absence of randomised controlled trials,7 
however, observational studies are the only available 
source of making risk:benefit decisions in relation to 
antidepressant use during pregnancy. It is well known 
that such studies are prone to confounding bias, 
which can persist even after adjustment for multiple 
confounders.17-19  Several approaches—such as pro-
pensity score matching, negative controls, and sibling 
control designs—have been suggested as strategies 
that could strengthen causal inference in observa-
tional studies18 but remain largely unused in investiga-
tions of this issue. To help to improve the 
understanding of the association between antidepres-
sant use during pregnancy and autism in offspring, we 
applied a range of such causal analytical methods on 
data from a large total population cohort in Stockholm 
County. We hypothesised that if the association 
between antidepressant use during pregnancy and 
autism was likely to be causal, the results would be 
consistent across a range of analytical methods with 
different strengths and limitations and underlying 
assumptions.
Methods
stockholm youth cohort
We used data from the Stockholm youth cohort, an 
intergenerational record linkage study comprising all 
individuals aged 0-17 living in Stockholm County in 
2001-11 (n=735 096). It contains prospectively recorded 
data on the cohort members and their first degree rela-
tives collected by record linkage with a range of national 
and regional healthcare, social, and administrative reg-
istries.20 21  The key for record linkage is the unique 
national identity numbers assigned to all Swedish resi-
dents. Figure 1 shows the derivation of the sample for 
our main analysis. We excluded cohort members born 
before 1996 as medication data were reliably collected 
only after this date. We also excluded individuals not 
linked to the medical birth register (such as those born 
abroad), those who could not be linked to their biologi-
cal mothers, adopted children, and those living in 
Stockholm County for less than four years. The resi-
dence requirement also allowed us to exclude children 
aged under 4 in whom a diagnosis of autism might be 
less reliable.
Patient involvement
As mandated by the ethical permission, no attempts 
were made to contact any cohort members for any 
aspect of this record linkage study. As such, cohort 
members were not involved in setting the research 
question or the outcome measures, nor were they 
involved in developing plans for the design or imple-
mentation of the study. No patients were asked to advise 
on interpretation or writing up of results. There are no 
plans to directly disseminate the results of the research 
to cohort members, but dissemination to the general 
public and relevant patient groups will be undertaken 
by using presentations and social media.
Medication use during pregnancy (exposure)
We derived information on maternal use of antidepres-
sants in pregnancy from the medical birth register 
(since 1997) and supplemented it with the prescribed 
drug register (available from July 2005).22 23  The medical 
birth register contains information on current medica-
tions being taken as reported by pregnant women at 
their antenatal interview, at a median of 10 weeks’ ges-
tation. The data are semi-automatically coded with 
World Health Organization anatomical therapeutic 
classification (ATC) codes. The medical birth register 
also contains free text data, which we processed using 
a computerised search for generic drug names and 
Swedish and international brand names of antidepres-
sants using fuzzy pattern matching to account for 
unknown abbreviations, non-standard terms, and mis-
spellings.24  The prescribed drug register contains data 
on drugs prescribed and dispensed in ambulatory care 
to the entire Swedish population, and the medications 
are coded with ATC codes. In the prescribed drug regis-
ter, we defined exposure to medication during preg-
nancy as a prescription up to 30 days before the start of 
the pregnancy (as estimated by the last menstrual 
period or evidence from ultrasonography) until the 
birth date of the child. We considered exposure to anti-
depressants if there was a record of these in either the 
medical birth register or the prescribed drug register. 
The validity of these two data sources have been 
reported previously.22 23 We cross validated these two 
data sources in our sample as data on antidepressant 
use were available in both registers for cohorts born in 
2006 and 2007. Among these, 280 women out of 318 
with a report of antidepressant use in the medical birth 
register were also recorded as having prescriptions for 
an antidepressant during pregnancy in the prescribed 
drug register (88.1%).
Children born in Sweden 1996-2007 (n=290 673)
Children born to 165 922 mothers (n=254 610)
ASD (n=5378 (2.1%); 4248 without intellectual disability, 1130 with intellectual disability)
Not in medical birth register (n=17 029)
Not linked to biological mother (n=41)
Adopted (n=210)
Not living in Stockholm County for ≥4 years
  (n=18 519)
No maternal indication for
  antidepressant use,* exposure to
antidepressants during pregnancy
(n=238 943)
ASD (n=4889; 3835 without intellectual
disability, 1054 with intellectual disability)
Maternal indication for antidepressant
use,* no exposure to antidepressants
during pregnancy (n=12 325)
ASD (n=353; 291 without intellectual
disability, 62 with intellectual disability)
Exposed to antidepressants
during pregnancy (n=3342)
ASD (n=136; 122 without intellectual
disability, 14 with intellectual disability)
Fig 1 | Derivation of sample from stockholm youth cohort used in main analysis of maternal 
use of antidepressants during pregnancy and autism in offspring. *Maternal indications for 
antidepressant use were anxiety disorders (F40-41), bipolar disorder (F30-31), depression/
mood disorder (F32-39), non-affective psychoses (F20-29), obsessive compulsive disorders 
(F42), stress related disorders (F43), and other neurotic disorders (F44-48)
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We coded the medications as any antidepressant 
(ATC code N06A) and also divided them into selective 
serotonin reuptake inhibitors (SSRI, ATC N06AB) and 
all other antidepressants. We also categorised antide-
pressants based on their affinities for the serotonin 
transporter into high versus medium or low affinity.2
ascertainment of autism with and without 
intellectual disability (outcome)
We have described the multisource ascertainment of 
autism in previous publications.7 20 21  In short, nearly all 
diagnoses of autism in Sweden are provided through its 
free and universally accessible system of health and 
care. We collected diagnostic information from the rele-
vant registers reflecting the pathways to diagnosis. 
These sources included diagnoses recorded in the 
national patient register, the Stockholm child and ado-
lescent mental health register, and the habilitation reg-
isters (ICD-9 (299), ICD-10 (F84), or DSM-IV (299) 
codes). We identified co-occurring intellectual disabil-
ity using ICD 9 (317-319), ICD-10 (F70-79), and DSM-IV 
(317-319) in the child or adult mental health registers or 
the national patient register. We have previously carried 
out two validation procedures— a case note validation 
study and a cross validation study of diagnosis of 
autism spectrum disorder with a national twin study—
and found a high validity of the diagnoses recorded in 
the registers.20
Other variables
Depression and other psychiatric disorders 
in parents
We used ICD-9 and 10 diagnoses recorded in the 
national patient register, which covers inpatient (with 
complete national coverage since 1973) and outpatient 
specialist care (since 2001) to ascertain depression and 
other maternal and paternal diagnoses of other psychi-
atric indications for antidepressants (anxiety disorder, 
bipolar disorder, non-affective psychoses, obses-
sive-compulsive disorder, other stress related and neu-
rotic disorders) any time before the birth of the child as 
described elsewhere.25  We supplemented these with 
diagnoses recorded from the Stockholm adult psychiat-
ric care register, which comprises all publicly financed 
psychiatric care in Stockholm County (constituting 85% 
of all such care) since 1997.26
We used prospectively collected data on maternal 
and paternal age at birth of child (continuous variables 
used as restricted cubic splines), fifths of family income 
adjusted for year of ascertainment and family size, 
highest education of either parent (≤9 years, 10-12 years, 
≥13 years), maternal country of birth (Sweden, Europe, 
other), parity (0, 1, 2, or more previous births) as poten-
tial confounders. We also used several other variables 
to construct the propensity score as described below. 
These included maternal smoking and body mass index 
(BMI) recorded at first antenatal visit, number of diag-
noses of maternal depression before birth, type of 
depression care (inpatient or outpatient), and a large 
range of maternal neurological and psychiatric condi-
tions diagnosed before birth (see appendix).
Main analysis
We used R-3.1.3 (R Foundation for Statistical Comput-
ing) for analysis. After descriptive analyses, we used the 
following analytic strategies to assess the risk of off-
spring autism in mothers with antidepressant use 
during pregnancy.
Analysis 1: risk estimates of autism in children of 
antidepressant users during pregnancy compared 
with those with psychiatric disorders but no 
antidepressant use
In our first analysis, we used logistic regression to 
derive odds ratios and their 95% confidence intervals as 
estimates of relative risks for autism in children of 
mothers who used antidepressants during pregnancy 
compared with those with a psychiatric disorder who 
did not use antidepressants. We used this stringent 
comparison group to better account for confounding by 
indication and because women without any psychiatric 
disorder would be ineligible in hypothesised ran-
domised controlled trials of this issue. We adjusted the 
model for birth year to control for period effects in med-
ication use and ascertainment of autism.21 We then 
adjusted for the presence or absence of specific individ-
ual maternal psychiatric disorders (depression, anxiety 
disorder, bipolar disorder, non-affective psychotic dis-
orders, obsessive-compulsive disorder, adjustment dis-
orders, post-traumatic stress disorders, and other 
neurotic disorders) that are indications for antidepres-
sant use (model 2) and additionally for child sex, paren-
tal ages, birth order, maternal education, family 
income, and maternal country of birth (model 3). We 
calculated population attributable fractions (PAF) 
using the fully adjusted model, estimating the propor-
tion of autism cases that would be prevented if no 
women with psychiatric disorders were prescribed anti-
depressants, assuming a causal association and no 
residual confounding. In a supplementary analysis, we 
restricted the above treatment group to mothers with 
antidepressant use who had a recorded psychiatric 
diagnosis. We also described the associations by the 
most commonly used individual antidepressants and 
grouped antidepressants as SSRI and non-SSRIs, and 
by their serotonin transporter receptor (SERT) affinity 
into high or low/medium affinity.
Analysis 2: propensity score matched analysis
In our second analysis, we calculated propensity score 
matched estimates for the above associations. Propen-
sity score matching helps to minimise the potential for 
confounding from observed variables by comparing 
exposed and unexposed individuals with similar char-
acteristics.27  We estimated propensity scores for antide-
pressant use during pregnancy using a boosted 
classification and regression tree model,28 from the 
above covariates and additional variables regarding 
maternal psychiatric disorders including indicators of 
severity such as the type of psychiatric care and number 
of previous care episodes for depression, and the use of 
other medications (see appendix for complete details). 
We matched children of women who did and did not 
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use antidepressants using the propensity score using a 
maximum of 4:1 unexposed:exposed nearest neighbour 
matching with a caliper of 0.20 SD and exact matching 
on birth year, sex of child, number of depression diag-
noses, anxiety disorders, and obsessive compulsive dis-
order. We estimated odds ratios and 95% confidence 
interval from cluster robust logistic regression models.
Analysis 3: outcome discordant matched sibling sets 
analysis
In our third analysis, we examined associations 
between maternal antidepressant use in pregnancy and 
autism spectrum disorder in matched sets of outcome 
discordant siblings (that is, sibling sets in which there 
is at least one affected sibling and one unaffected sib-
ling, see appendix). Siblings share up to half of their 
genetic makeup and generally share their early postna-
tal environment. Sibling analysis can be a powerful 
method to control for unmeasured confounders, such 
as maternal genetic liability for neuropsychiatric condi-
tions, when the confounders are shared more than the 
exposure.29 We derived odds ratios and confidence 
intervals using conditional logistic regression models 
adjusted for sex, parity, and birth year.
Analysis 4: comparison with risk estimates for 
paternal antidepressant use during pregnancy as 
negative control
In our fourth analysis, we used paternal use of antide-
pressant as a negative control exposure with the 
assumption that the fathers would share many of the 
unmeasured confounders with mothers, and, if a simi-
lar heightened risk of autism was observable with pater-
nal and maternal use of antidepressants, the 
associations would be unlikely to reflect an in utero 
effect of the medications.30 In these analyses, we used 
data for the individuals born in 2006 and 2007, for 
whom we had data on antidepressant prescriptions for 
the mothers and fathers, and estimated the associa-
tions of antidepressant prescriptions in fathers during 
the time of the mother’s pregnancy with the outcomes.
sensitivity analysis
In a sensitivity analysis, we estimated how robust the 
estimates of associations between antidepressant expo-
sure and autism spectrum disorder were to unmeasured 
confounding in our propensity score matched sample. 
We assumed a binary confounder U increased the risk of 
autism and was more prevalent in antidepressant users 
than in non-antidepressant users. Given specified 
parameters such as the relation of U with autism spec-
trum disorder and the prevalence of U in antidepressant 
users and non-users, we estimated odds ratios and 95% 
confidence interval corrected for this unmeasured con-
founder, specified over a range of plausible parameters.31
Missing data
There were few missing data on the key variables in our 
main analysis (total 1.5% missing data). More data were 
missing in some variables used in the generation of pro-
pensity scores, but the boosted classification and 
regression tree model is able to incorporate missing val-
ues in the prediction (see appendix).
Results
Table 1 shows the descriptive statistics of the cohort in 
relation to exposure to antidepressants during preg-
nancy or mental disorders. Of the 3342 children exposed 
to antidepressants during pregnancy, 136 (4.1%) had a 
diagnosis of autism. The comparison group included 
12 325 children of mothers with a psychiatric disorder 
who did no use antidepressants during pregnancy, of 
whom 353 (2.9%) had a diagnosis of autism. Of the 
238 943 cohort children for whom there was no record of 
maternal history of psychiatric disorder or antidepres-
sant use during pregnancy, 4889 had autism (2.1%). The 
sample sizes for all of the other analyses are provided in 
the appendix.
Exposure to antidepressants during pregnancy was 
associated with a higher odds of a diagnosis of autism 
in offspring than exposure to a maternal psychiatric dis-
order without antidepressants (adjusted odds ratio 1.45, 
95% confidence interval 1.13 to 1.85; table 2). This asso-
ciation was observed only for autism without intellec-
tual disability (1.57, 1.21 to 2.04). The results were similar 
when we restricted the antidepressant exposure group 
to mothers who had a recorded psychiatric diagnosis 
(table A in appendix). If we assume an unconfounded 
causal association, the corresponding population 
attributable fractions suggested that about 2% of autism 
cases would be prevented if no pregnant woman with a 
psychiatric disorder took antidepressants (2.1%, 95% 
confidence interval −0.7% to 4.7%).
The propensity score analysis led to similar results to 
those found with conventional regression models (table 
3  and appendix). The numbers were smaller for the sib-
ling control analyses, but results again seemed consis-
tent, though with wider confidence intervals that 
included 1 (table 3  and appendix). In our negative con-
trol analysis, there was no evidence of an increased risk 
of autism in children whose fathers were prescribed 
antidepressants during the mothers’ pregnancy 
(adjusted odds ratio 1.13, 95% confidence interval 0.68 
to 1.88), but the association with maternal prescriptions 
for antidepressants continued to be observed (1.69, 1.06 
to 2.72; table 4). In all analyses, the risk estimates were 
greater for individuals without intellectual disability 
than those with intellectual disability.
In sensitivity analysis, the results seemed to be mod-
erately robust to unmeasured confounding (table B in 
appendix). Tables C and D in the appendix show the 
rates and associations of autism in children exposed to 
the most commonly prescribed individual antidepres-
sants, also grouped into SSRI and non-SSRI antidepres-
sants as well as by their serotonin receptor affinity. 
Although imprecision because of small numbers is evi-
dent, the rates of autism seemed to be higher in chil-
dren of mothers who used clomipramine and 
venlafaxine and lowest in users of paroxetine. Similar 
associations were observed for SSRI and non-SSRI anti-
depressants in relation to risk. The point estimates for 
the risk of autism in children of users of low/moderate 
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table 1 | selected characteristics of stockholm youth cohort. Figures are numbers (percentage) unless stated otherwise
exposed to 
antidepressants during 
pregnancy (n=3342)
Maternal psychiatric disorder 
and unexposed to 
antidepressants (n=12 325)
no maternal psychiatric 
disorder and unexposed to 
antidepressants (n=238 943)
Autism spectrum disorder (ASD) 136 (4.1) 353 (2.9) 4889 (2.1)
 ASD without intellectual disability 122 (3.7) 291 (2.4) 3835 (1.6)
 ASD with intellectual disability 14 (0.4) 62 (0.5) 1054 (0.4)
Mean (SD) maternal age (years) 31.7 (5.2) 31.5 (5.4) 30.7 (5.0)
Mean (SD) paternal age (years) 34.0 (6.4) 34.0 (6.6) 33.7 (6.1)
Male child 1727 (51.7) 6446 (52.3) 122 354 (51.2)
Parity:
 1 1673 (50.1) 5203 (42.2) 108 192 (45.3)
 2 951 (28.4) 4248 (34.5) 87 765 (36.7)
 ≥3 718 (21.5) 2874 (23.3) 42 986 (18.0)
Maternal education >12 years 1382 (41.3) 4897 (39.7) 110 017 (46.0)
Family income in highest fifth 904 (27.1) 3306 (26.8) 83 190 (34.8)
Mother born in Sweden 2,713 (81.2) 9176 (74.5) 177 395 (74.2)
Mother smoked 512 (15.3) 1434 (11.6) 16 996 (7.1)
Maternal BMI at 1st antenatal visit:
 Normal (18.5-<25) 1741 (52.1) 6035 (49.0) 129 597 (54.2)
 Underweight (<18.5) 81 (2.4) 316 (2.6) 5590 (2.3)
 Overweight (25-<30) 619 (18.5) 2272 (18.4) 40 212 (16.8)
 Obese (≥30) 328 (9.8) 981 (8.0) 13 945 (5.8)
 Missing 573 (17.2) 2721 (22.1) 49 599 (20.8)
Maternal lifetime psychiatric diagnoses before birth:
 Depression 1378 (41.3) 5800 (47.1) 0
 Anxiety disorder 685 (20.5) 2594 (21.1) 0
 Bipolar disorder 70 (2.1) 402 (3.3) 0
 Non-affective psychoses 46 (1.4) 645 (5.2) 0
 Obsessive-compulsive disorder 56 (1.7) 139 (1.1) 0
 Stress related disorders 389 (11.7) 4261 (34.6) 0
 Other neurotic disorders 89 (2.7) 1202 (9.8) 0
No of diagnoses of maternal depression before birth:
 0 1964 (58.8) 6525 (52.9) 238 943 (100)
 1 517 (15.5) 3287 (26.7) 0
 2 240 (7.2) 1128 (9.2) 0
 3 172 (5.2) 508 (4.1) 0
 ≥4 449 (13.4) 877 (7.1) 0
No of diagnoses of maternal depression before birth by treatment:
 Specialist care:
  0 2337 (69.9) 8018 (65.1) 238 943 (100)
  1 388 (11.6) 2493 (20.2) 0
  2 199 (6.0) 952 (7.7) 0
  3 418 (12.5) 862 (7.0) 0
 Primary care:
  0 3059 (91.5) 11 766 (95.5) 238 943 (100)
  1 129 (3.9) 286 (2.3) 0
  ≥2 154 (4.6) 273 (2.2) 0
 Inpatient diagnosis:
  0 2,982 (89.2) 10 938 (88.8) 238 943 (100)
  1 229 (6.9) 969 (7.9) 0
  2 70 (2.1) 233 (1.9) 0
  ≥3 61 (1.8) 184 (1.5) 0
 Other:
  0 3201 (95.8) 12 042 (97.7) 238 943 (100)
  1 105 (3.1) 232 (1.9) 0
  ≥2 36 (1.1) 51 (0.4) 0
Medications during pregnancy:
 SSRI antidepressants 2710 (81.1) — 0
 Non-SSRI antidepressants 723 (21.6) — 0
 Antiepileptics 37 (1.1) 73 (0.6) 490 (0.2)
 Antipsychotics 106 (3.2) 166 (1.4) 347 (0.2)
 Anxiolytics 314 (9.4) 191 (1.6) 337 (0.1)
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SERT affinity seemed to be greater than that in children 
of users of high serotonin transporter affinity antide-
pressants, though the confidence intervals overlapped.
discussion
Principal findings
In this large Swedish population based study, we car-
ried out several analyses to further investigate the asso-
ciation between antidepressant use during pregnancy 
and autism in offspring. Our main findings were that 
children exposed to antidepressants during pregnancy 
seemed to be at a higher risk of autism, particularly 
autism without intellectual disability, than children of 
mothers with psychiatric disorders who were not 
treated with antidepressants during pregnancy. The 
findings seemed to be consistent across traditional 
regression methods, propensity score matching, and a 
sibling set comparison, and maternal exposure to anti-
depressants during pregnancy had a strong association 
with the outcomes whereas no such association was 
observed with paternal exposure. This points to a 
potential effect of antidepressant use on the risk of 
autism beyond any effect caused by confounding by the 
underlying condition. It is important to note, however, 
that the absolute risk was small, and 4.1% of children 
exposed to antidepressants in utero had autism com-
pared with 2.9% of those with a maternal history of psy-
chiatric disorder. We estimated that only about 2% of 
autism cases in this population would be theoretically 
prevented, if the association was causal and no women 
with psychiatric disorders used antidepressants during 
pregnancy.
strengths and limitations
The main strengths of this study were the large sample 
size and the range of analyses carried out to strengthen 
causal inference beyond traditional methods. As the 
study included the total population of Stockholm 
County and benefited from multisource ascertainment 
of cases, as opposed to studies that rely on hospital dis-
charge diagnoses, the findings are likely to have high 
external validity. The possibility of misclassification of 
exposure cannot be ruled out, but the availability of 
both self reported information from the medical birth 
register and dispensation information from the pre-
scribed drug register was an advantage.22 23 As the 
absence of detailed measures of severity of depression 
during pregnancy was a limitation, we used propensity 
scores to match and therefore balance exposure groups 
using a wide range of relevant characteristics. Because 
of small numbers, we were not able to assess trimester 
specific or dose response effects.
Comparison with other studies
This study builds on our previous case-control study,7 
now enhanced with a larger sample, a more stringent 
comparison group of mothers with psychiatric disor-
ders, and a range of causal inference methods including 
propensity score matching, a sibling comparison, and a 
negative control design to strengthen confidence in the 
results. Although several large register based studies 
have been carried out to date, the number of children 
with autism who were also prenatally exposed to anti-
depressants has been small, and some studies seemed 
to have substantially under-ascertained autism. This 
has led to imprecise estimates, which have been perva-
sive in all studies on this topic, including those that 
have concluded that the association is likely to be 
explained by confounding.6 8  Unlike some previous 
studies, we were unable to study discontinuation of 
antidepressants before pregnancy as an additional neg-
ative control as the prescribed drug register was opera-
tional only since 2005 and thus had insufficient 
numbers. It should be noted that as a large proportion 
of women discontinue drug treatment during preg-
nancy,32  the cohorts that did have such data2 10 11 had 
more statistical power to find an effect in the discontin-
uation group, as opposed to effects in those who contin-
ued treatment during pregnancy. The upper limits of 
the estimates of the associations reported in these stud-
ies were consistent with the results we report.
table 3 | Matching estimated odds ratios and 95% confidence interval for associations between antidepressant use 
during pregnancy and autism spectrum disorder (asD)
Outcome
Propensity score matched analysis* sibling matched analysis†
exposed/
unexposed Or (95% Ci)
affected sibling 
sets/exposed Or (95% Ci)
ASD 1608/4818 1.68 (1.23 to 2.30) 3038/66 1.36 (0.84 to 2.20)
ASD without intellectual disability 1601/4801 1.76 (1.26 to 2.46) 2408/60 1.57 (0.92 to 2.66)
ASD with intellectual disability 1552/4721 1.25 (0.52 to 3.03) 630/6 0.78 (0.24 to 2.54)
*Propensity score matched estimates of associations of antidepressant use during pregnancy and ASD in children exposed prenatally to antidepressants 
compared with children exposed to maternal psychiatric disorder but no antidepressants.
†Outcome discordant sibling matched estimates for associations of antidepressant use during pregnancy and ASD. Conditional logistic regression 
models adjusted for sex, parity, and birth year.
table 2 | regression estimated odds ratios and 95% confidence intervals for associations 
between antidepressant use during pregnancy and autism spectrum disorder (asD) in 
children exposed prenatally to antidepressants compared with children exposed to 
maternal psychiatric disorders but no antidepressants (combined n=15 667) in cluster 
robust logistic regression models (cluster=birth mother)
Outcome (no of exposed cases) Model 1* Model 2† Model 3‡
ASD (136) 1.47 (1.20 to 1.81) 1.47 (1.16 to 1.87) 1.45 (1.13 to 1.85)
ASD without intellectual disability (122) 1.59 (1.28 to 1.98) 1.62 (1.25 to 2.08) 1.57 (1.21 to 2.04)
ASD with intellectual disability (14) 0.87 (0.49 to 1.57) 0.81 (0.39 to 1.68) 0.72 (0.38 to 1.77)
*Adjusted for birth year.
†Additionally adjusted for maternal psychiatric disorders diagnosed before birth (depression, anxiety disorder, 
bipolar disorder, non-affective psychotic disorders, obsessive-compulsive disorder, stress related disorders, 
other neurotic disorders), maternal medications used during pregnancy (antiepileptics, antipsychotics, 
anxiolytics).
‡Additionally adjusted for sex, maternal age, paternal age, parity, maternal education, family income, maternal 
birth country.
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Meaning of the findings
The different analyses we used have different strengths 
and limitations, but their findings seemed to triangu-
late, pointing towards an association between mater-
nal antidepressant use in pregnancy and autism in 
offspring. On the other hand, the increased risk was 
seen largely for autism without intellectual disability, 
a phenotype that has been shown to be more herita-
ble,33  which could suggest a role for unmeasured 
genetic confounding. Although the results of our sib-
ling control analyses were consistent with the other 
approaches we used, the numbers were low, leading to 
an imprecise result. Larger sibling comparisons in the 
future could elucidate the role of genetic confounding 
in this  relation. Furthermore, higher point estimates 
for lower serotonin transporter receptor affinity anti-
depressants, several of which are prescribed for more 
severe depression,2 could suggest a role of confound-
ing by severity of depression, which is difficult to mea-
sure in record linkage studies such as this one. Taken 
together, it is difficult to conclusively dismiss the pos-
sibility that the observed associations are wholly 
attributable to confounding. We simulated the poten-
tial impact of unmeasured confounding, which sug-
gested that such an unmeasured confounder would 
have to be a strong risk factor for autism, exerting a 
confounding influence above and beyond the multiple 
covariates already controlled for in the propensity 
score matching.
Clinical implications
So what should families and doctors making decisions 
about antidepressants during pregnancy make of such 
results? Firstly, this and other studies clearly suggest 
that there is an increased background risk of autism in 
children of women with psychiatric conditions, regard-
less of antidepressant treatment. Secondly, despite the 
observed relative risks, over 95% of women who took 
antidepressants during pregnancy did not have a child 
with autism. And, finally, if a causal link were robustly 
established, and if no pregnant women took antide-
pressants during pregnancy, only 2% of autism cases in 
this population would be prevented. It is known that 
pregnant women perceive such risks as greater than 
they are,34 and a balanced discussion in relation to clin-
ical decision making in the light of evolving but yet 
inconsistent evidence is important. On the other hand, 
given that this association might not solely be the 
byproduct of confounding by indication, it is important 
to continue investigation of possible underlying biolog-
ical mechanisms that could help us to better under-
stand the aetiology of autism.
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